TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11142548
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for generalized anxiety disorder (GAD)
Study: 24838406
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n=201)
Study: 20370938
Drug: Dietary group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary group (DG) receiving daily 1200 mg Ca and 7.5 microg vitamin D3 for the first 12 months, then 1200 mg Ca and 22.5 microg vitamin D3 for the next 18 months through fortified dairy products
Study: 18840700
Drug: Stuttering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuttering treatment efficacy research
Study: 10217232
Drug: rBPI21 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI21 (4 mg x kg(‐1) x d(‐1) for 2 consecutive days)
Study: 10217232
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent volume by continuous infusion)
Study: 80219
Drug: Perhexiline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline (300 to 400 mg per day)
Study: 30205115
Drug: Genotype-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided warfarin dosing (CYP2C9, VKORC1, and CYP4F2)
Study: 30205115
Drug: Clinical-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical-guided warfarin dosing
Study: 24890623
Drug: 2L-PEG preparations
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L-PEG preparations
Study: 24890623
Drug: 2-glasses solutions
Normalized name: Red arsenic glass
DrugBank: Tetraarsenic tetrasulfide (DB19141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-glasses solutions
Study: 24890623
Drug: 4L-PEG preparations
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4L-PEG preparations
Study: 20206571
Drug: Pulsed dose-rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dose-rate (PDR) brachytherapy with optimized dose distribution
Study: 20206571
Drug: Iridium wires
Normalized name: iridium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iridium wires (traditional treatment)
Study: 18608313
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy combined with imipramine
Study: 18608313
Drug: Graded in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded in vivo exposure treatment combined with imipramine
Study: 18608313
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment combined with imipramine
Study: 18608313
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy combined with imipramine
Study: 18608313
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy combined with placebo
Study: 18608313
Drug: Graded in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded in vivo exposure treatment combined with placebo
Study: 18608313
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment combined with placebo
Study: 18608313
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy combined with placebo
Study: 10659548
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg levofloxacin
Study: 8680689
Drug: L-NAME (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (nonselective NOS inhibitor)
Study: 8680689
Drug: Aminoguanidine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoguanidine (selective inhibitor of inducible NOS)
Study: 30763138
Drug: Sol-Gel Silica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sol-Gel Silica Infiltration (SG)
Study: 28373993
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg/day (group A, n = 31)
Study: 26071673
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (COC)
Study: 10090432
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg oral loading dose followed by 200 mg/d for 10 days)
Study: 10090432
Drug: Comparator therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator therapies (erythromycin, cefaclor, ofloxacin, clarithromycin, and ciprofloxacin)
Study: 10090432
Drug: Comparator therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator therapies
Study: 7727835
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17‐propionate preparation under occlusion
Study: 7727835
Drug: Corticoid‐free cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticoid‐free cream under occlusion
Study: 7727835
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment and occlusion (aluminium chamber)
Study: 7727835
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment and no occlusion
Study: 6873608
Drug: Loperamide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (6 mg at 5 h and at 30 min before the meal)
Study: 27385022
Drug: Tolvaptan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (15 mg) with fixed dose of diuretics
Study: 27385022
Drug: Tolvaptan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (15 mg) with half-dose of diuretics
Study: 27385022
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Tolvaptan with fixed dose and half-dose of diuretics)
Study: 15194017
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus simvastatin 10 mg
Study: 15194017
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus simvastatin 20 mg
Study: 15194017
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus simvastatin 40 mg
Study: 9311407
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 2.1 ml/h (low rate group)
Study: 9311407
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 6.3 ml/h (high rate group)
Study: 7506178
Drug: Nimesulide 50
Normalized name: nimesulide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 50 mg/dose
Study: 7506178
Drug: Lysine-acetylsalicylate 720
Normalized name: Acetylsalicylate
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine-acetylsalicylate 720 mg/dose
Study: 2882339
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (subcutaneous calcium heparin, 12,500 IU daily)
Study: 2882339
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual therapy)
Study: 28581346
Drug: Online cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive-behavioral therapy group program - 'Recapture Life'
Study: 9218069
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m. (OME20)
Study: 9218069
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg o.m. (OME10)
Study: 9218069
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d. (RAN)
Study: 9218069
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg weekends (OMEW)
Study: 3661107
Drug: Ketanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 10 mg i.v.
Study: 3661107
Drug: Droperidol 5
Normalized name: droPERidol 5 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5 mg i.v.
Study: 3661107
Drug: Hydergine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine 0.9 mg i.v.
Study: 24631589
Drug: LY545694 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 (2 doses)
Study: 24631589
Drug: LY545694 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 (3 doses)
Study: 24631589
Drug: LY545694 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 (all doses)
Study: 19930764
Drug: 5-6 g
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-6 g beta-glucan
Study: 19930764
Drug: 8-9 g
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-9 g beta-glucan
Study: 16914415
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture line (Group A2)
Study: 14696461
Drug: Interferon Alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon Alfa-2a (4.5 million units daily for 16 weeks) plus Lamivudine (100 mg daily starting from week 5 for 48 weeks)
Study: 14696461
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (100 mg daily for 48 weeks)
Study: 8649661
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent chlorhexidine solution applied with an interdental brush
Study: 8649661
Drug: 0.1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 percent quinine solution (control) applied with an interdental brush
Study: 8649661
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent chlorhexidine solution
Study: 8649661
Drug: 0.1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 percent quinine solution (control)
Study: 1434863
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of fentanyl citrate
Study: 1434863
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous administration of morphine
Study: 2864794
Drug: Mianserin 60
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 60 mg
Study: 29405603
Drug: Autologous umbilical
Normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous umbilical cord blood (AUCB) infusion
Study: 24939813
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control condition
Study: 20412459
Drug: Caudal levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal levobupivacaine 0.125% (group L)
Study: 20412459
Drug: Caudal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal tramadol 1.5 mg.kg(‐1) (group T)
Study: 12120807
Drug: Valerian treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian treatment
Study: 9179964
Drug: Aqueous propolis
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous propolis extract NIVCRISOL administered during the cold season 1994-1995
Study: 339438
Drug: Horse antilymphoblast
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse antilymphoblast globulin (ALG) 20 mg/kg/day for 10 days
Study: 339438
Drug: Human IgG
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human IgG 20 mg/kg/day for 10 days (Control)
Study: 21883874
Drug: Active PENS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PENS therapy
Study: 16762076
Drug: Dietary nucleotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary nucleotide supplementation (500 mg capsule three times a day for 56 days)
Study: 16762076
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg capsule three times a day for 56 days)
Study: 15017564
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy for Stage I‐II patients
Study: 15017564
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB) for Stage III‐IV patients
Study: 8468734
Drug: Chemotherapy (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Cisplatin + 5‐Fu) and radiation
Study: 2948826
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 1.5 pmol X kg‐1 X min‐1 for 30 min followed by 15 pmol X kg‐1 X min‐1 for a further 30 min
Study: 2948826
Drug: Matching vehicle
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle infusions (control)
Study: 3154686
Drug: Molsidomine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (12 to 24 mg/day orally; initial 20 mg i.v. followed by infusion of 1 to 4 mg/hour)
Study: 30877209
Drug: Increased treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased treatment
Study: 30877209
Drug: Unchanged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged treatment
Study: 30877209
Drug: Reduced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced treatment
Study: 30877209
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with tocilizumab for GCA and tumor necrosis factor inhibitors for TA
Study: 29142236
Drug: Interferon-alpha (IFN-α)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-α) therapy with a scoring model composed of miR-210, miR-22, and alanine aminotransferase (ALT)
Study: 25441251
Drug: TLC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC diet with 0.5 cup of soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Study: 12659385
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol plus ipratropium
Study: 11153621
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding solution enriched with vitamins A (67 microg/dL), C (13.3 mg/dL), and E (4.94 mg/dL)
Study: 11153621
Drug: Isocaloric and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric and isonitrogenous control solution
Study: 9244718
Drug: TEPT-guided antiarrhythmic
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEPT-guided antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Study: 9244718
Drug: Empiric antiarrhythmic
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Study: 9244718
Drug: TEPT-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEPT-guided therapy
Study: 3897351
Drug: Single vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vision (standard treatment) group
Study: 31892611
Drug: 600 IUs/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IUs/day of oral vitamin D3
Study: 31892611
Drug: 4,000 IUs/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 IUs/day of oral vitamin D3
Study: 31892611
Drug: 10,000 IUs/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IUs/day of oral vitamin D3
Study: 27006113
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor antagonist (sulpiride 400 mg)
Study: 25015680
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of oral tyrosine
Study: 25015680
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral tyrosine
Study: 25015680
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of oral tyrosine
Study: 25015680
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of oral tyrosine
Study: 10808389
Drug: Celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200 mg)
Study: 7210690
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration of Oxazepam
Study: 28859993
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (gel)
Study: 28859993
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (other formulations)
Study: 26081567
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa targeting hemoglobin (Hb) levels of 11-13 g/dL
Study: 26081567
Drug: Low Hb
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Hb group maintained at 9.0-11.0 g/dL using epoetin alfa
Study: 24614074
Drug: Naso-gastric infusion
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naso-gastric infusion of chocolate milk (stomach distention + nutrients)
Study: 24614074
Drug: Naso-gastric infusion
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naso-gastric infusion of water (stomach distention)
Study: 24614074
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of chocolate milk (stomach distention + nutrients + oral exposure)
Study: 20527136
Drug: 85% formic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85% formic acid in distilled water solution
Study: 16272420
Drug: Telephone mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone mode of G-CAHPS survey
Study: 16272420
Drug: Mail mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mail mode of G-CAHPS survey
Study: 11906502
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg single dose)
Study: 11906502
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg twice daily for 3 days)
Study: 9759984
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg twice daily for 3 months)
Study: 7799050
Drug: Calcium mupirocin
Normalized name: Mupirocin Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium mupirocin ointment administered intranasally for five days
Study: 3197372
Drug: Local nervous
Normalized name: Syzygium nervosum flower bud extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nervous blockade (lignocaine 3.7 x 10(‐4)‐7.4 x 10(‐2) mol/l)
Study: 28457980
Drug: Fresh Frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh Frozen Plasma (FFP) 15 mL/kg of bodyweight
Study: 28457980
Drug: Coagulation Factor
Normalized name: Coagulation factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulation Factor Concentrates (CFC) primarily fibrinogen concentrate 50 mg/kg of bodyweight
Study: 21263100
Drug: Biweekly intravenous
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly intravenous dactinomycin 1.25 mg/m²
Study: 21263100
Drug: Weekly intramuscular
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intramuscular (IM) methotrexate 30 mg/m²
Study: 15042325
Drug: 18F-desmethoxyfallypride (18F-DMFP)
Normalized name: (18F)-Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-desmethoxyfallypride (18F-DMFP) PET imaging after injection of 180-200 MBq
Study: 9126305
Drug: 5'-DFUR (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR (mean 9,000 mg) preoperatively
Study: 9126305
Drug: No anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticancer agents (Control group B)
Study: 7984719
Drug: Popping air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Popping air capsules for 5 minutes (experimental group)
Study: 24274771
Drug: Cocoa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa treatment (37 g/d of dark chocolate and a sugar-free cocoa beverage, total cocoa = 22 g/d, total flavanols = 814 mg/d)
Study: 24274771
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (low-flavanol chocolate bar and a cocoa-free beverage, total flavanols = 3 mg/d)
Study: 19064532
Drug: Cocoa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa treatment
Study: 22170713
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (IGC; n=20; glucose goal, 80‐140 mg/dl)